The estimated Net Worth of Rebecca Taub is at least 134 百万$ dollars as of 8 April 2024. Rebecca Taub owns over 2,676 units of Madrigal Pharmaceuticals Inc stock worth over 107,570,275$ and over the last 8 years he sold MDGL stock worth over 21,135,784$. In addition, he makes 5,269,840$ as President of Research and Development、 Chief Medical Officer、 Director at Madrigal Pharmaceuticals Inc.
Rebecca has made over 3 trades of the Madrigal Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 2,676 units of MDGL stock worth 25,288$ on 8 April 2024.
The largest trade he's ever made was exercising 73,888 units of Madrigal Pharmaceuticals Inc stock on 3 April 2024 worth over 698,242$. On average, Rebecca trades about 10,721 units every 152 days since 2016. As of 8 April 2024 he still owns at least 461,675 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Rebecca Taub stock trades at the bottom of the page.
Dr. Rebecca A. Taub M.D. serves as President of Research and Development, Chief Medical Officer, Director of the Company. Dr. Taub served on the board of directors of Private Madrigal and as Chief Executive Officer of Private Madrigal from its inception in September 2011 through the Merger in July 2016. Prior to joining Private Madrigal, Dr. Taub served as Senior Vice President, Research and Development of VIA Pharmaceuticals from 2008 to 2011 and as Vice President, Research, Metabolic Diseases at Hoffmann-La Roche from 2004 to 2008. In those positions, Dr. Taub oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases including the conduct of a series of Phase I and II proof of conduct clinical trials. Dr. Taub led drug discovery including target identification, lead optimization and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company, in a variety of positions, including Executive Director of CNS and metabolic diseases research. Before becoming a pharmaceutical executive, Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania, and remains an adjunct professor. Dr. Taub is the author of more than 120 research articles. Before joining the faculty of the University of Pennsylvania, Dr. Taub served as an Assistant Professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College. Dr. Taub and Dr. Friedman, our Chief Executive Officer and Chairman of the Board of Directors, are married.
As the President of Research and Development、 Chief Medical Officer、 Director of Madrigal Pharmaceuticals Inc, the total compensation of Rebecca Taub at Madrigal Pharmaceuticals Inc is 5,269,840$. There are 1 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of 6,093,190$.
Rebecca Taub is 68, he's been the President of Research and Development、 Chief Medical Officer、 Director of Madrigal Pharmaceuticals Inc since 2019. There are 6 older and 11 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.
Rebecca's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428.
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over 471,222,585$ worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth 79,114,183$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Paul A Friedman、Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of 20,602,093$. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth 1,551,490$.
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include: